We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study.
OBJECTIVE: To estimate the prevalence of spondyloarthropathies (SpA) in an adult population in Marche, a region located in central Italy.
METHODS: A cross-sectional population-based study was conducted on a target adult population of 20 882. Questionnaires were sent to a random sample of 3664 individuals aged 18 years and over, selected from the lists of 16 general practices. Trained rheumatologists carried out structured visits in which respondent subjects were asked about symptoms of back pain, peripheral arthritis, joint swelling, psoriasis, and the occurrence of diarrhoea and dysuria. A family history of rheumatic disease, psoriasis, or uveitis was assessed. Cases were further classified as ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis (ReA), inflammatory bowel disease (IBD)-associated arthritis, and undifferentiated SpA by the European Spondyloarthropathy Study Group (ESSG) criteria.
RESULTS: A total of 2155 subjects participated to the study (response rate 58.8%). Twenty-three cases of SpA (18 men, five women, mean age 48.3 +/- 12.1 years) were confirmed, with an overall prevalence of 1.06% [95% confidence interval (CI) 0.78-1.38]. The most common SpA was PsA, with a prevalence of 0.42% (95% CI 0.31-0.61), followed by AS with 0.37% (95% CI 0.23-0.49). Two cases with undifferentiated SpA, two with ReA, and two with IBD-associated arthritis were also observed (0.09%, 95% CI 0.04-0.16).
CONCLUSIONS: This is the first population-based study that provides an estimate of the prevalence of SpA in Italy. PsA and AS were the most common SpA subsets. Further epidemiological studies are needed to obtain reliable prevalence rates and to better understand our findings.
METHODS: A cross-sectional population-based study was conducted on a target adult population of 20 882. Questionnaires were sent to a random sample of 3664 individuals aged 18 years and over, selected from the lists of 16 general practices. Trained rheumatologists carried out structured visits in which respondent subjects were asked about symptoms of back pain, peripheral arthritis, joint swelling, psoriasis, and the occurrence of diarrhoea and dysuria. A family history of rheumatic disease, psoriasis, or uveitis was assessed. Cases were further classified as ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis (ReA), inflammatory bowel disease (IBD)-associated arthritis, and undifferentiated SpA by the European Spondyloarthropathy Study Group (ESSG) criteria.
RESULTS: A total of 2155 subjects participated to the study (response rate 58.8%). Twenty-three cases of SpA (18 men, five women, mean age 48.3 +/- 12.1 years) were confirmed, with an overall prevalence of 1.06% [95% confidence interval (CI) 0.78-1.38]. The most common SpA was PsA, with a prevalence of 0.42% (95% CI 0.31-0.61), followed by AS with 0.37% (95% CI 0.23-0.49). Two cases with undifferentiated SpA, two with ReA, and two with IBD-associated arthritis were also observed (0.09%, 95% CI 0.04-0.16).
CONCLUSIONS: This is the first population-based study that provides an estimate of the prevalence of SpA in Italy. PsA and AS were the most common SpA subsets. Further epidemiological studies are needed to obtain reliable prevalence rates and to better understand our findings.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app